(AOF) – Biosynex has signed an agreement to acquire 100% of the capital of the Italian company Bigix Pharma from its founding partners. The finalization of this acquisition will take place in the coming days, after completion of the formalities required in Italy. Bigix Pharma already has a customer portfolio of more than 5,000 pharmacies, approached by its sales force, made up of more than 40 independent sales agents.
Bigix Pharma distributes various product lines in the medical equipment segment and achieved in 2021 a turnover of approximately 2.9 million euros.
With this acquisition, Biosynex will be able to penetrate the Italian Pharmacy market, which represents more than 20,000 points of sale, and launch its own ranges of self-tests, thermometers, mosquito repellents, hot water bottles under Disney license and other products. catalog headlights.
After the opening of two subsidiaries in Switzerland in 2020 and in Benelux in June 2022, Bigix Pharma becomes the 3rd European subsidiary of Biosynex in Italy, thus strengthening the European network of pharmacies and parapharmacies with more than 50,000 points of sale visited directly by group sales forces.
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial exploitation or not, creation of a hypertext link or reuse in any way whatsoever of this information is subject to the prior written consent of OPTION. FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from the sources it considers the safest. However, subject to its gross negligence, OPTION FINANCES SAS and its contributors do not in any way guarantee the absence of error and defects, even hidden ones, nor the exhaustive nature or the lack of conformity for any use whatsoever of this data and of OPTION FINANCE SAS or one of its contributors, and cannot be held responsible for any delays or interruptions that may affect access to them. The user of the OPTION FINANCE SAS service will use the AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.
Receive our latest news
Every morning, the information to remember on the financial markets.